| . | Group 1 . | Group 2 . | Group 3 . | Group 4 . | Group 5 . | Group 6 . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | n = 18 . | n = 12 . | n = 18 . | n = 10 . | n = 11 . | n = 16 . | P value . | ||||||
| Myositis specific Antibody, n (%) | anti-TIF1γ | 14 (77.8) | anti-MDA5 | 12 (100) | anti-ARS | 18 (100) | anti-SRP | 8 (80.0) | NA | NA | |||
| anti-Mi2 | 3 (16.7) | anti-HMGCR | 2 (20.0) | ||||||||||
| anti-NXP2 | 1 (5.5) | ||||||||||||
| Muscle biopsy, n (%) | 10 | (55.5) | 4 | (33.3) | 10 | (55.6) | 9 | (90.0) | 8 | (72.7) | 15 | (93.8) | 0.006 |
| MRI | |||||||||||||
| Upper arm, n (%) | 17 | (94.4) | 12 | (100) | 18 | (100) | 9 | (90) | 10 | (90.9) | 16 | (100) | |
| Thigh, n (%) | 16 | (88.9) | 10 | (83.3) | 17 | (94.4) | 10 | (100) | 8 | (72.7) | 15 | (93.8) | |
| Lower leg, n (%) | 0 | (0) | 0 | (0) | 0 | (0) | 2 | (20.0) | 1 | (9.1) | 1 | (6.2) | |
| EULAR/ACR classification | |||||||||||||
| DM, n (%) | 17 | (94.4) | 4 | (33.3) | 11 | (61.1) | 1 | (10.0) | 7 | (63.6) | 0 | (0) | |
| ADM, n (%) | 1 | (5.55) | 8 | (66.7) | 4 | (22.2) | 1 | (10.0) | 4 | (36.4) | 0 | (0) | |
| PM, n (%) | 0 | (0) | 0 | (0) | 3 | (16.7) | 8 | (80.0) | 0 | (0) | 16 | (100) | |
| Age at diagnosis, years (IQR) | 62.5 | (54.3–68.5) | 53 | (44.3-62.3) | 53 | (44.7–63.3) | 62 | (44.5–67.0) | 64 | (55.0–70.0) | 69 | (58.3–73.5) | 0.046 |
| Sex (male/female) | 5/13 | 2/10 | 2/16 | 2/8 | 3/8 | 3/13 | 0.84 | ||||||
| CK, U/L (IQR) | 885 | (308.8–2770) | 185 | (50.50-308.5) | 654 | (215.0–1606) | 5736 | (1638–6303) | 712 | (164.0–1746) | 1096 | (623.8–1945) | <0.001 |
| Time from onset, months (IQR) | 3.1 | (1.89–5.89) | 2.2 | (1.70–3.31) | 4.8 | (2.58–8.02) | 6.6 | (4.77–10.9) | 5.1 | (3.07–6.75) | 6.8 | (5.48–17.3) | 0.002 |
| Gottron sign, n (%) | 18 | (100) | 12 | (100) | 15 | (83.3) | 2 | (20.0) | 11 | (100) | 0 | (0.0) | |
| Dysphagia, n (%) | 8 | (44.4) | 0 | (0) | 1 | (5.6) | 6 | (60.0) | 2 | (18.2) | 3 | (18.8) | 0.001 |
| Interstitial lung disease, n (%) | 1 | (5.56) | 12 | (100) | 18 | (100) | 6 | (60) | 9 | (81.8) | 2 | (12.5) | <0.001 |
| Malignancy, n (%) | 8 | (44.4) | 0 | (0.0) | 3 | (16.7) | 1 | (10) | 4 | (36.4) | 1 | (6.2) | 0.014 |
| Muscle weakness, n (%) | 17 | (94.4) | 4 | (33.3) | 14 | (77.8) | 9 | (90.0) | 7 | 63.6) | 16 | (100) | <0.001 |
| . | Group 1 . | Group 2 . | Group 3 . | Group 4 . | Group 5 . | Group 6 . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | n = 18 . | n = 12 . | n = 18 . | n = 10 . | n = 11 . | n = 16 . | P value . | ||||||
| Myositis specific Antibody, n (%) | anti-TIF1γ | 14 (77.8) | anti-MDA5 | 12 (100) | anti-ARS | 18 (100) | anti-SRP | 8 (80.0) | NA | NA | |||
| anti-Mi2 | 3 (16.7) | anti-HMGCR | 2 (20.0) | ||||||||||
| anti-NXP2 | 1 (5.5) | ||||||||||||
| Muscle biopsy, n (%) | 10 | (55.5) | 4 | (33.3) | 10 | (55.6) | 9 | (90.0) | 8 | (72.7) | 15 | (93.8) | 0.006 |
| MRI | |||||||||||||
| Upper arm, n (%) | 17 | (94.4) | 12 | (100) | 18 | (100) | 9 | (90) | 10 | (90.9) | 16 | (100) | |
| Thigh, n (%) | 16 | (88.9) | 10 | (83.3) | 17 | (94.4) | 10 | (100) | 8 | (72.7) | 15 | (93.8) | |
| Lower leg, n (%) | 0 | (0) | 0 | (0) | 0 | (0) | 2 | (20.0) | 1 | (9.1) | 1 | (6.2) | |
| EULAR/ACR classification | |||||||||||||
| DM, n (%) | 17 | (94.4) | 4 | (33.3) | 11 | (61.1) | 1 | (10.0) | 7 | (63.6) | 0 | (0) | |
| ADM, n (%) | 1 | (5.55) | 8 | (66.7) | 4 | (22.2) | 1 | (10.0) | 4 | (36.4) | 0 | (0) | |
| PM, n (%) | 0 | (0) | 0 | (0) | 3 | (16.7) | 8 | (80.0) | 0 | (0) | 16 | (100) | |
| Age at diagnosis, years (IQR) | 62.5 | (54.3–68.5) | 53 | (44.3-62.3) | 53 | (44.7–63.3) | 62 | (44.5–67.0) | 64 | (55.0–70.0) | 69 | (58.3–73.5) | 0.046 |
| Sex (male/female) | 5/13 | 2/10 | 2/16 | 2/8 | 3/8 | 3/13 | 0.84 | ||||||
| CK, U/L (IQR) | 885 | (308.8–2770) | 185 | (50.50-308.5) | 654 | (215.0–1606) | 5736 | (1638–6303) | 712 | (164.0–1746) | 1096 | (623.8–1945) | <0.001 |
| Time from onset, months (IQR) | 3.1 | (1.89–5.89) | 2.2 | (1.70–3.31) | 4.8 | (2.58–8.02) | 6.6 | (4.77–10.9) | 5.1 | (3.07–6.75) | 6.8 | (5.48–17.3) | 0.002 |
| Gottron sign, n (%) | 18 | (100) | 12 | (100) | 15 | (83.3) | 2 | (20.0) | 11 | (100) | 0 | (0.0) | |
| Dysphagia, n (%) | 8 | (44.4) | 0 | (0) | 1 | (5.6) | 6 | (60.0) | 2 | (18.2) | 3 | (18.8) | 0.001 |
| Interstitial lung disease, n (%) | 1 | (5.56) | 12 | (100) | 18 | (100) | 6 | (60) | 9 | (81.8) | 2 | (12.5) | <0.001 |
| Malignancy, n (%) | 8 | (44.4) | 0 | (0.0) | 3 | (16.7) | 1 | (10) | 4 | (36.4) | 1 | (6.2) | 0.014 |
| Muscle weakness, n (%) | 17 | (94.4) | 4 | (33.3) | 14 | (77.8) | 9 | (90.0) | 7 | 63.6) | 16 | (100) | <0.001 |
The P values were derived from Fisher’s exact test or Kruskal–Wallis test across groups.
ADM: amyopathic dermatomyositis; DM: dermatomyositis; IQR: interquartile range; PM: polymyositis.
| . | Group 1 . | Group 2 . | Group 3 . | Group 4 . | Group 5 . | Group 6 . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | n = 18 . | n = 12 . | n = 18 . | n = 10 . | n = 11 . | n = 16 . | P value . | ||||||
| Myositis specific Antibody, n (%) | anti-TIF1γ | 14 (77.8) | anti-MDA5 | 12 (100) | anti-ARS | 18 (100) | anti-SRP | 8 (80.0) | NA | NA | |||
| anti-Mi2 | 3 (16.7) | anti-HMGCR | 2 (20.0) | ||||||||||
| anti-NXP2 | 1 (5.5) | ||||||||||||
| Muscle biopsy, n (%) | 10 | (55.5) | 4 | (33.3) | 10 | (55.6) | 9 | (90.0) | 8 | (72.7) | 15 | (93.8) | 0.006 |
| MRI | |||||||||||||
| Upper arm, n (%) | 17 | (94.4) | 12 | (100) | 18 | (100) | 9 | (90) | 10 | (90.9) | 16 | (100) | |
| Thigh, n (%) | 16 | (88.9) | 10 | (83.3) | 17 | (94.4) | 10 | (100) | 8 | (72.7) | 15 | (93.8) | |
| Lower leg, n (%) | 0 | (0) | 0 | (0) | 0 | (0) | 2 | (20.0) | 1 | (9.1) | 1 | (6.2) | |
| EULAR/ACR classification | |||||||||||||
| DM, n (%) | 17 | (94.4) | 4 | (33.3) | 11 | (61.1) | 1 | (10.0) | 7 | (63.6) | 0 | (0) | |
| ADM, n (%) | 1 | (5.55) | 8 | (66.7) | 4 | (22.2) | 1 | (10.0) | 4 | (36.4) | 0 | (0) | |
| PM, n (%) | 0 | (0) | 0 | (0) | 3 | (16.7) | 8 | (80.0) | 0 | (0) | 16 | (100) | |
| Age at diagnosis, years (IQR) | 62.5 | (54.3–68.5) | 53 | (44.3-62.3) | 53 | (44.7–63.3) | 62 | (44.5–67.0) | 64 | (55.0–70.0) | 69 | (58.3–73.5) | 0.046 |
| Sex (male/female) | 5/13 | 2/10 | 2/16 | 2/8 | 3/8 | 3/13 | 0.84 | ||||||
| CK, U/L (IQR) | 885 | (308.8–2770) | 185 | (50.50-308.5) | 654 | (215.0–1606) | 5736 | (1638–6303) | 712 | (164.0–1746) | 1096 | (623.8–1945) | <0.001 |
| Time from onset, months (IQR) | 3.1 | (1.89–5.89) | 2.2 | (1.70–3.31) | 4.8 | (2.58–8.02) | 6.6 | (4.77–10.9) | 5.1 | (3.07–6.75) | 6.8 | (5.48–17.3) | 0.002 |
| Gottron sign, n (%) | 18 | (100) | 12 | (100) | 15 | (83.3) | 2 | (20.0) | 11 | (100) | 0 | (0.0) | |
| Dysphagia, n (%) | 8 | (44.4) | 0 | (0) | 1 | (5.6) | 6 | (60.0) | 2 | (18.2) | 3 | (18.8) | 0.001 |
| Interstitial lung disease, n (%) | 1 | (5.56) | 12 | (100) | 18 | (100) | 6 | (60) | 9 | (81.8) | 2 | (12.5) | <0.001 |
| Malignancy, n (%) | 8 | (44.4) | 0 | (0.0) | 3 | (16.7) | 1 | (10) | 4 | (36.4) | 1 | (6.2) | 0.014 |
| Muscle weakness, n (%) | 17 | (94.4) | 4 | (33.3) | 14 | (77.8) | 9 | (90.0) | 7 | 63.6) | 16 | (100) | <0.001 |
| . | Group 1 . | Group 2 . | Group 3 . | Group 4 . | Group 5 . | Group 6 . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | n = 18 . | n = 12 . | n = 18 . | n = 10 . | n = 11 . | n = 16 . | P value . | ||||||
| Myositis specific Antibody, n (%) | anti-TIF1γ | 14 (77.8) | anti-MDA5 | 12 (100) | anti-ARS | 18 (100) | anti-SRP | 8 (80.0) | NA | NA | |||
| anti-Mi2 | 3 (16.7) | anti-HMGCR | 2 (20.0) | ||||||||||
| anti-NXP2 | 1 (5.5) | ||||||||||||
| Muscle biopsy, n (%) | 10 | (55.5) | 4 | (33.3) | 10 | (55.6) | 9 | (90.0) | 8 | (72.7) | 15 | (93.8) | 0.006 |
| MRI | |||||||||||||
| Upper arm, n (%) | 17 | (94.4) | 12 | (100) | 18 | (100) | 9 | (90) | 10 | (90.9) | 16 | (100) | |
| Thigh, n (%) | 16 | (88.9) | 10 | (83.3) | 17 | (94.4) | 10 | (100) | 8 | (72.7) | 15 | (93.8) | |
| Lower leg, n (%) | 0 | (0) | 0 | (0) | 0 | (0) | 2 | (20.0) | 1 | (9.1) | 1 | (6.2) | |
| EULAR/ACR classification | |||||||||||||
| DM, n (%) | 17 | (94.4) | 4 | (33.3) | 11 | (61.1) | 1 | (10.0) | 7 | (63.6) | 0 | (0) | |
| ADM, n (%) | 1 | (5.55) | 8 | (66.7) | 4 | (22.2) | 1 | (10.0) | 4 | (36.4) | 0 | (0) | |
| PM, n (%) | 0 | (0) | 0 | (0) | 3 | (16.7) | 8 | (80.0) | 0 | (0) | 16 | (100) | |
| Age at diagnosis, years (IQR) | 62.5 | (54.3–68.5) | 53 | (44.3-62.3) | 53 | (44.7–63.3) | 62 | (44.5–67.0) | 64 | (55.0–70.0) | 69 | (58.3–73.5) | 0.046 |
| Sex (male/female) | 5/13 | 2/10 | 2/16 | 2/8 | 3/8 | 3/13 | 0.84 | ||||||
| CK, U/L (IQR) | 885 | (308.8–2770) | 185 | (50.50-308.5) | 654 | (215.0–1606) | 5736 | (1638–6303) | 712 | (164.0–1746) | 1096 | (623.8–1945) | <0.001 |
| Time from onset, months (IQR) | 3.1 | (1.89–5.89) | 2.2 | (1.70–3.31) | 4.8 | (2.58–8.02) | 6.6 | (4.77–10.9) | 5.1 | (3.07–6.75) | 6.8 | (5.48–17.3) | 0.002 |
| Gottron sign, n (%) | 18 | (100) | 12 | (100) | 15 | (83.3) | 2 | (20.0) | 11 | (100) | 0 | (0.0) | |
| Dysphagia, n (%) | 8 | (44.4) | 0 | (0) | 1 | (5.6) | 6 | (60.0) | 2 | (18.2) | 3 | (18.8) | 0.001 |
| Interstitial lung disease, n (%) | 1 | (5.56) | 12 | (100) | 18 | (100) | 6 | (60) | 9 | (81.8) | 2 | (12.5) | <0.001 |
| Malignancy, n (%) | 8 | (44.4) | 0 | (0.0) | 3 | (16.7) | 1 | (10) | 4 | (36.4) | 1 | (6.2) | 0.014 |
| Muscle weakness, n (%) | 17 | (94.4) | 4 | (33.3) | 14 | (77.8) | 9 | (90.0) | 7 | 63.6) | 16 | (100) | <0.001 |
The P values were derived from Fisher’s exact test or Kruskal–Wallis test across groups.
ADM: amyopathic dermatomyositis; DM: dermatomyositis; IQR: interquartile range; PM: polymyositis.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
